VANCOUVER, March 17 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to announce that iCo-009 has been highlighted in a leading drug delivery
journal, Advanced Drug Delivery Reviews. The paper discusses the development
of a novel oral Amphotericin B (AmpB) formulation ("iCo-009") with significant
antifungal activity, minimal kidney toxicity, and enhanced oral absorption of
The publication, "Enhanced drug absorption using lipids: A case study
presenting the development and pharmacological evaluation of a novel
lipid-based oral Amphotericin B formulation for the treatment of systemic
fungal infections", provides further detail on the potential mechanisms by
which oral iCo-009 knocks down fungal infections.
- iCo-009 significantly decreased (95%) organ fungal concentration of
Aspergillus fumigatus compared to controls in the brain and the
spleen, two organs where Aspergillus fumigatus typically localizes in
this animal model.
- iCo-009 shows enhanced gastrointestinal tract absorption, plasma
concentration, and tissue distribution.
- iCo-009 shows minimal renal toxicity.
- iCo-009 significantly decreased plasma galactomannan antigen levels.
Detection of galactomannan in the blood can be used to diagnose
Aspergillus fumigatus infections in humans.
"iCo continues to be impressed by the work of Drs. Kishor & Ellen Wasan,"
stated Andrew Rae, President & CEO of iCo Therapeutics. "Their work continues
to improve upon the iCo-009 formulation represented in the paper, with newer
formulations showing even more dramatic anti-fungal activity and
bioavailability. iCo-009 has the potential to treat not just systemic fungal
infections, but also parasitical diseases such as Leishmaniasis in the
developing world. iCo remains very committed to UBC's global access policy and
we look forward to proceeding with development in both markets."
iCo has an option agreement with The University of British Columbia (UBC)
for iCo-009's development, which also represents a new drug delivery
technology with the potential to reprofile other IV administered drugs to the
oral route of administration. iCo plans to develop iCo-009 under the 505(b)(2)
section of the Federal Food, Drug, and Cosmetic Act, which expressly permits
the FDA to reference safety data not developed by the applicant for approval
of a New Drug Application (NDA).
The paper is available in the March 17, 2008 edition of Advanced Drug
Delivery Reviews. K. Sachs-Barrable, S. Lee, E. Wasan, S. Thornton, K. Wasan.
Advanced Drug Delivery Reviews 60 (2008) 692-701.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to two products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, and iCo-008, a product
with Phase II clinical history to be developed for severe ocular allergies.
iCo Therapeutics also has an exclusive option to license iCo-009, a oral
reformulation of Amphotericin B for sight and life-threatening diseases.
iCo- 009 also represents a new drug delivery technology with the potential to
reprofile other IV administered drugs to the oral route of administration.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol
For more information, visit the company website at:
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
For further information: Business Development Contact: Dr. John Clement,
CT&DO, (778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414
x 224; Investor/Media Contact: Frederica Bell, Corporate Development, (604)
602-9414 x 228